N10-TFA-PTE-L-GLU-L-半胱氨酸 | 1041170-98-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: N10-TFA-PTE-L-GLU-L-半胱氨酸
• 英文名称: N10-Tfa-Pte-L-Glu-L-Cys
• 英文别名: Unk-N(Tfa)4Abz-gGlu-Cys-OH；(2S)-2-[[4-[(2-amino-4-oxo-3H-pteridin-6-yl)methyl-(2,2,2-trifluoroacetyl)amino]benzoyl]amino]-5-[[(1R)-1-carboxy-2-sulfanylethyl]amino]-5-oxopentanoic acid
• CAS: 1041170-98-2
• 化学式: C₂₄H₂₃F₃N₈O₈S
• 分子量: 640.6
• InChiKey: UYPSAMXOZWVHJI-KBPBESRZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.9
• 重原子数：
  44
• 可旋转键数：
  12
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  247
• 氢给体数：
  7
• 氢受体数：
  15

文献信息

• Imaging and therapeutic method using monocytes
  申请人：Low S. Philip

  公开号：US20070009434A1

  公开（公告）日：2007-01-11

  The invention relates to a method of treating or diagnosing a disease state mediated by monocytes. The method utilizes a composition comprising a conjugate or complex of the general formula A b -X wherein the group A b comprises a ligand that binds to monocytes, and when the conjugate is being used for treatment of the disease state, the group X comprises an immunogen, a cytotoxin, or a compound capable of altering monocyte function, and when the conjugate is being used for diagnosing the disease state, the group X comprises an imaging agent.

  本发明涉及一种治疗或诊断由单核细胞介导的疾病状态的方法。该方法利用包含一种复合物或复合物的组合物，其一般公式为Ab-X的组合物，其中Ab组含与单核细胞结合的配体，当该复合物用于治疗疾病状态时，组X包含免疫原、细胞毒素或能够改变单核细胞功能的化合物，当该复合物用于诊断疾病状态时，组X包含成像剂。
• Combined Muta- and Semisynthesis: A Powerful Synthetic Hybrid Approach to Access Target Specific Antitumor Agents Based on Ansamitocin P3
  作者：Florian Taft、Kirsten Harmrolfs、Irinia Nickeleit、Anja Heutling、Miriam Kiene、Nisar Malek、Florenz Sasse、Andreas Kirschning

  DOI：10.1002/chem.201101640

  日期：2012.1.16

  showed good to strong antiproliferative activity (IC50 <10 nM) for different cancer cell lines. Finally, the four conjugates were exposed to two cancer cell lines [cervix carcinoma, KB‐3‐1 (FR+) and lung carcinoma, A‐459 (FR−)], the latter devoid of the membrane‐bound folic acid receptor (FR−). All four conjugates showed strong antiproliferative activity for the FR+ cancer cell line but were inactive

  据报道，四种新的肿瘤特异性叶酸/阿米托星偶联物的获得依赖于基于突变合成和半合成相结合的合成策略。分别通过突变合成或改良的发酵方案制备了两种溴化安那托霉素衍生物，它们是在Stille条件下半合成引入烯丙基胺连接基的起点。一系列标准的偶联步骤将蝶酸/谷氨酸/半胱氨酸单元引入到修饰的安托霉素中。所有新的衍生物，包括那些预期在叶酸/阿米托星共轭物内化到癌细胞中以及二硫键还原还原后产生的衍生物，都显示出良好的至强的抗增殖活性（IC 50 <10 n M）用于不同的癌细胞系。最后，将四种结合物暴露于两种癌细胞系中[子宫颈癌，KB-3-1（FR +）和肺癌，A-459（FR-）]，后者没有膜结合叶酸受体（FR -）。所有四种结合物均对FR +癌细胞系表现出强大的抗增殖活性，但对FR-细胞系无活性。所追求的合成策略是基于突变合成和半合成的组合，并被证明对于获取难以通过全合成制备的新的安索霉素衍生物具有强大的作用。
• [EN] METHODS FOR ENHANCEMENT OF ENGINEERED CELL THERAPIES IN CANCER TREATMENT<br/>[FR] PROCÉDÉS D'AMÉLIORATION DE THÉRAPIES CELLULAIRES MODIFIÉES DANS LE TRAITEMENT DU CANCER
  申请人：PURDUE RESEARCH FOUNDATION

  公开号：WO2022147576A1

  公开（公告）日：2022-07-07

  Methods are provided for reprogramming M2 -like macrophages to Ml -like macrophages, which reverses the proinflammatory to anti-inflammatory shift observed during the course of certain cancers, co-administered with one or more types of engineered cells such as, without limitation, CAR T-cells, engineered natural killer cells, engineered stem cells or the like. The compounds comprise an immune modulator that targets a pattern recognition receptor of a cell and are specific to the cells of interest through the incorporation of a targeting moiety (e.g., folate or a functional fragment or analog thereof). Releasable and/or non-releasable linkers can be included and engineered to facilitate the optimal delivery of the immune modulator. The compounds and compositions can be employed in one or more methods of treatment for cancers.

  提供了一种将M2型巨噬细胞重新编程为M1型巨噬细胞的方法，这可以逆转某些癌症过程中观察到的促炎症到抗炎症的转变，与一种或多种工程细胞（例如CAR T细胞，工程自然杀伤细胞，工程干细胞等）共同使用。这些化合物包括一个免疫调节剂，其靶向细胞的模式识别受体，并通过纳入靶向基团（例如叶酸或其功能性片段或类似物）特异性地作用于感兴趣的细胞。可以包括可释放和/或不可释放的连接剂，并设计为促进免疫调节剂的最佳输送。这些化合物和组合物可以用于一个或多个癌症治疗方法。
• WO2021007277A5
  申请人：——

  公开号：WO2021007277A5

  公开（公告）日：2023-07-14
• Design and synthesis of releasable folate–drug conjugates using a novel heterobifunctional disulfide-containing linker
  作者：Apparao Satyam

  DOI：10.1016/j.bmcl.2008.04.063

  日期：2008.6

  Cellular uptake of vitamin folic acid occurs via folate-receptor mediated endocytosis. Many types of cancer cells express high levels of folate receptors as they need continuous supply of this vitamin for their proliferation. With an objective to use folic acid as a 'Trojan Horse' to transport anticancer drugs into cancer cells, a novel heterobifunctional disulfide-containing linker was synthesized and utilized to covalently link an amino-and hydroxyl-containing anticancer drug, and an appropriately functionalized folic acid to create novel targetable folate-drug conjugates that are shown to release free drugs under biologically relevant pH via sulfhydryl-assisted cleavage of the self-immolative disulfide-containing linker. (C) 2008 Elsevier Ltd. All rights reserved.